Cardiff Oncology

CRDF

Market cap $185M

Cardiff Oncology (CRDF) remains a single-asset biotech, with its thesis reliant on onvansertib targeting PLK1 in difficult-to-treat cancers. Recent phase 2 CRDF-004 data showed diminished response rates for onvansertib versus earlier readouts, though both doses outperformed control. Cash runway extends into Q1 2027, but future large-scale trials will likely require significant additional funding.

SAN DIEGO, Dec. 08, 2025 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers, today announced that clinical data from an investigator-sponsored trial with onvansertib in chronic myelomonocytic leukemia (CMML) will be presented in a poster presentation at the 67th American Society of Hematology (ASH) Annual Meeting.

SAN DIEGO, Dec. 08, 2025 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers, today announced that company management will present and host one-on-one meetings at Sidoti's Year-End Virtual Investor Conference, which is taking place from December 10-11, 2025.

SAN DIEGO, Nov. 24, 2025 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers, today announced that company management will participate in a fireside chat and 1x1 investor meetings at the Piper Sandler 37th Annual Healthcare Conference, which is taking place from December 2-4, 2025.

– Announced positive data from the ongoing Phase 2 CRDF-004 trial evaluating onvansertib + standard of care for the treatment of first-line RAS-mutated metastatic colorectal cancer – – Expects to report an update from the Phase 2 CRDF-004 trial in Q1 2026 – – Cash and investments of $60.6 million as of September 30, 2025, projected runway into Q1 2027 – SAN DIEGO, Nov. 06, 2025 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers, today announced financial results for the third quarter ended September 30, 2025, and provided a business update. “This quarter was marked by highly encouraging data from our ongoing CRDF-004 trial evaluating onvansertib in combination with standard of care for first-line RAS-mutated mCRC.

SAN DIEGO, Nov. 04, 2025 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers, today announced that company management will participate in two upcoming investor conferences in November 2025.

Cardiff Oncology is a speculative buy, driven by the potential of onvansertib as a first-in-class PLK1 inhibitor for first-line RAS-mutated mCRC. CRDF's Q1 2026 data readout for onvansertib is a pivotal catalyst, with positive results potentially unlocking blockbuster sales and significant share price appreciation. Key risks include clinical trial execution, capital needs, and heavy reliance on onvansertib as the sole pipeline asset, justifying a conviction rating of 3 out of 5.

Cardiff Oncology receives a 'Buy' rating, driven by promising clinical data and strategic leadership for long-term investors. CRDF's lead candidate, onvansertib, shows strong efficacy and safety in Phase 2 trials for RAS-mutated metastatic colorectal and triple-negative breast cancers. Despite competition and clinical-stage risks, onvansertib's unique PLK1 inhibition mechanism offers breakthrough potential in multi-billion-dollar cancer markets.

SAN DIEGO, Oct. 02, 2025 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers, today announced that company management will participate in two upcoming investor conferences in October 2025.

SAN DIEGO, Aug. 28, 2025 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers, today announced that company management will participate in the three upcoming investor conferences in September 2025. Details of the events can be found below.